Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393754 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults
A Phase 3 study, sponsored by VBI Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,607
- Enrollment target
NCT03393754 is a Phase 3 study that has completed, run by VBI Vaccines. The registered enrollment target is 1,607 participants.
The verdict
NCT03393754, a Phase 3 study, has completed, sponsored by VBI Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,607 participants
- Enrollment target
Study Summary
This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac® compared to Engerix-B® in adults ≥ 18 years old and the superiority of Sci-B-Vac® compared to Engerix-B® in ≥ 45 years old.
Interventions
- BIOLOGICAL Hepatitis B Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,607 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2019-04-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03393754
The ClinicalTrials.gov registry entry for NCT03393754 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VBI Vaccines, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hepatitis B Vaccination is the first listed.
NCT03393754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03393754 about?
NCT03393754 is a clinical study titled "Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults". This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac® compared to Engerix-B® in adults ≥ 18 years old and the superiority of Sci-B-Vac® compared to Engerix-B® in ≥ 45 years old.
What is the current status of trial NCT03393754?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,607 participants. The study started on 2017-12-13. Estimated completion is 2019-04-08.
What interventions are being tested in trial NCT03393754?
The interventions under investigation include: Hepatitis B Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT03393754?
This trial is sponsored by VBI Vaccines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.